#USA #Biomanufacturing #Hopkinton #Phosphorex #John Rigg

John Rigg Takes Helm as Chairman at Phosphorex

In a significant development, Phosphorex, a leading contract development and manufacturing organization (CDMO) focused on drug delivery technologies, has appointed John Rigg as its new Chairman of the Board. This leadership change comes at a crucial time as the demand for innovative drug delivery systems continues to soar in the pharmaceutical and biotechnology fields.

John Rigg joined Phosphorex's board in 2024 and has since been instrumental in shaping the company's strategic direction and growth. With over two decades of extensive leadership experience in the pharmaceutical sector, Rigg has held pivotal roles in various companies. Notably, he served as the CEO of NanoImaging Services and Exelead Biopharma, where he was renowned for his expertise in complex injectable formulations and lipid nanoparticle (LNP) drug delivery systems. His earlier career stages included leadership positions at Ventria Bioscience and Eli Lilly and Company, amplifying his valuable background in operations and biomanufacturing.

Rigg's proven track record in the industry makes him a fitting choice for this elevated role. As Phosphorex embarks on an exciting phase of expansion and enhancement of its capabilities, Rigg's strategic insight is poised to provide a concrete advantage. He will guide the organization as it continues to innovate in formulation optimization, process design, and analytical development across its range of platforms, which include lipid and polymeric nanoparticles as well as microspheres.

Jerry Williamson, the CEO of Phosphorex, expressed great confidence in Rigg's capabilities. He remarked, "John has been an extremely valued board member, and his elevation to Chairman reflects our confidence in his strategic judgment. Drug delivery expertise has never been more important for therapeutic success. Having someone of John's caliber will allow us to accelerate our growth and further establish our leadership in the industry."

Rigg, sharing his excitement about his new role, stated, "Phosphorex has cultivated a truly unique organization with a deep-rooted understanding of particulate drug delivery. I look forward to contributing more significantly, especially as we navigate an era where the industry is increasingly recognizing the crucial role of effective drug delivery solutions in achieving clinical success."

As Phosphorex marks over 20 years in operation, it is well-positioned amidst a growing demand for specialized drug delivery expertise, driven by advances in nucleic acid medicines and targeted therapies. The company's flexible and innovative solutions aim to optimize the release rates and targeting capabilities of drugs, minimizing adverse outcomes for patients.

Phosphorex offers a spectrum of services to pharmaceutical and biotechnology companies, supplanting their complex challenges from the early phases of development to clinical trials. Their commitment is to help partners navigate the intricacies of drug development, ensuring promising therapies reach those in need.

Further information about Phosphorex and its offerings can be found on their official website at www.phosphorex.com or via their LinkedIn page. As the company envisions its future under John Rigg's guidance, the pharmaceutical landscape could see transformative advancements in drug delivery efficacy, paving the way for groundbreaking therapies that optimize patient outcomes.